C4 Therapeutics, Inc. (CCCC)

NMS – Real vaqt narxi. Valyuta: USD

3.17

0.00 (0.00%)

Yopilishda: May 12, 2026, 4:00 PM EDT

3.19

+0.02 (0.51%)

Bozor oldidan: May 13, 2026, 8:27 AM EDT

Kompaniya haqida

C4 Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, kasallik qo'zg'atuvchi oqsillarni parchalash uchun yangi terapevtik nomzodlarni ishlab chiqadi. Uning asosiy mahsulot nomzodi Cemsidomide bo'lib, bu og'iz orqali yuboriladigan, IKZF1 va IKZF3 yoki IKZF1/3 ga yo'naltirilgan monodak bo'lib, ko'p miyelomada bir nechta davolash liniyalari bo'yicha ehtiyojni qondirish uchun mo'ljallangan, bu uning 1-bosqichini yakunlagan. Kompaniya, shuningdek, o'pkaning mayda hujayrali rakida L858R mutatsiyasiga ega bo'lgan epidermal o'sish omili retseptorining og'iz orqali yuboriladigan, allosterik, mutantga selektiv bidak degraderi bo'lgan CFT8919 onkologik mahsulot nomzodini va yallig'lanish, neyroinflamasyon va neyrodegeneratsiyaga qaratilgan yangi degradatorlarni ishlab chiqmoqda. Uning F. Hoffmann-La Roche Ltd va Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd. va Merck KGAA bilan strategik hamkorliklari mavjud. Qo'shimcha ravishda, u saratonni davolash uchun Degrader-Antibody Conjugatesni ishlab chiqish bo'yicha Roche Holding AG bilan hamkorlik shartnomasiga ega. Kompaniya 2015 yilda ro'yxatga olingan va Massachusets shtatining Uoterdaun shahrida joylashgan.

Asosiy rahbarlar

Ism	Lavozim
Dr. Isabel Chiu Ph.D.	Senior Vice President of Strategic Alliances & Business Development
Dr. Kenneth C. Anderson M.D., Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board
Dr. Leonard M. J. Reyno M.D.	Chief Medical Officer
Dr. Nathanael S. Gray Ph.D.	Co-Founder & Member of Scientific Advisory Board
Mr. Andrew J. Hirsch M.B.A.	CEO, President & Director
Mr. Mark Mossler